BNBX — BNB Plus Corp.

Summary of Applied DNA Sciences Q1 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $1.2 million, up from $891,000 in Q1 2024, driven by increased product revenue from DNA tagging and isotopic testing services.
• Operating Loss: $3 million, improved from $3.8 million year-over-year, attributed to lower selling, general, and administrative expenses.
• Net Loss: $2.7 million, compared to $1.1 million in the prior year, with a note on unrealized gains affecting this figure.
• Adjusted EBITDA: Negative $2.9 million, an improvement from negative $3.2 million in Q1 2024.
• Cash Position: Cash and cash equivalents totaled $9.3 million as of December 31, 2024, down from $6.4 million at the end of September 2024, with an average monthly cash burn of approximately $1.2 million.

2. Strategic Updates and Business Highlights

• Strategic Restructuring: Aimed at reducing cash burn and focusing on the LineaRx subsidiary, which is expected to drive future growth.
• Exit from DNA Tagging Business: The company is winding down its DNA tagging segment, with a workforce reduction of about 20% and a one-time charge of $300,000.
• GMP Site Certification: The operational certification of the GMP Site One facility is a crucial milestone, enabling the company to produce DNA at scale and enter long-term supplier agreements.
• New Product Launch: Introduction of Linea Donor DNA for CRISPR applications, with plans for GMP availability later in the year.

3. Forward Guidance and Outlook

• Focus on LineaRx: The company is prioritizing its enzymatic DNA production capabilities, with expectations for increased customer engagement and project entries into clinical trials in 2025.
• Sales Pipeline: A robust pipeline for GMP IVT templates is anticipated, with initial revenue opportunities ranging from $50,000 to $3 million per contract.
• Growth Strategy: Plans to expand product offerings beyond IVT templates, leveraging a low CapEx model for growth and profitability.

4. Bad News, Challenges, or Points of Concern

• Going Concern Warning: The company disclosed substantial doubt regarding its ability to continue as a going concern, dependent on successful execution of its business plan and capital generation.
• Workforce Reduction: The exit from the DNA tagging segment and associated layoffs may impact operational capacity and morale.
• Market Competition: The competitive landscape in the biotherapeutics market remains intense, with the need to differentiate from established players in DNA production.

5. Notable Q&A Insights

• CRISPR Market Potential: The new Linea Donor DNA product is seen as a significant opportunity, particularly in the growing CRISPR therapy market, although it is less mature than the mRNA market.
• Revenue Drivers: Revenue increases in Q1 were attributed to existing customer contracts and increased volume in isotopic testing services rather than new customer acquisitions.
• Clinical Trial Dynamics: The phase one CAR T trial in Prague is expected to take about 18 months, with the potential for validation but uncertain revenue implications due to its hospital-based nature.

This summary encapsulates the key points discussed during the earnings call, highlighting both the opportunities and challenges faced by Applied DNA Sciences as they navigate their restructuring and focus on growth through their LineaRx subsidiary.